Source: Eur Respir J 2007; 30: 763-768
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Tremblay A., Mason C., Michaud G., van der Giessen L. J., Gosselink R., Hop W. C. J., Tiddens H. A. W. M.. Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?. Eur Respir J 2007; 30: 763-768

Member's Comments

No comment yet.

Related content which might interest you: Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis Source: Eur Respir J 2002; 19: 294-302 Year: 2002 RhDNase after airway clearance therapy improves peripheral airway patency in children with cystic fibrosis Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs Year: 2006 α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients Source: Eur Respir J 2007; 29: 240-250 Year: 2007 Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis Source: Eur Respir J 2011; 37: 1091-1095 Year: 2011 Effects of DNase on pulmonary function and exercise capacity in cystic fibrosis (CF) Source: Eur Respir J 2001; 18: Suppl. 33, 127s Year: 2001 Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis Source: Eur Respir J 2002; 20: 122-126 Year: 2002 The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Supressive antimicrobial therapy in chronic bronchial infection: the example of cystic fibrosis Source: Annual Congress 2011 - Chronic bronchial infection: more than a syndrome Year: 2011 Reporting specific airway resistance (sRaw) in children: mean or median? Source: Annual Congress 2006 - Landmark developments in lung function testing: 2006 Year: 2006 The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis Source: Eur Respir J 2011; 37: 806-812 Year: 2011 The prevalence and characteristics of intravenous (IV) antibiotics allergy in adult patient with cystic fibrosis (CF) Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice Source: Eur Respir J 2011; 37: 72-78 Year: 2011 Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011 Intervention trials and ventilation distribution in mild cystic fibrosis lung disease: will it all come out in the wash? Source: Eur Respir J 2011; 37: 757-759 Year: 2011 New insights into the pathophysiology of lung disease in cystic fibrosis patients Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=1 Year: 2006 Combination of inhaled corticosteroids and long acting beta two agonists improve lung clearance index (LCI) in preschoolers with cystic fibrosis Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge Year: 2011 Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis Source: Annual Congress 2013 –Cystic fibrosis: lung function and change of lung function in infants and children before and after treatment Year: 2013 Gene therapy for cystic fibrosis: successes and challenges Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=79 Year: 2006 Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016 Year: 2017